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Radical cystectomy (RC) is the gold standard treatment for muscle invasive bladder cancer 
(BC) [1]. It offers the best chance of cure in patients with curable disease and excellent 
palliation in those with local symptoms from advanced disease. Longitudinal reports suggest 
many patients accept and adapt to the impact of RC, leading to minimal overall impact on 
their quality of life [2]. As such, cystectomy also offers a viable alternative to BCG for patients 
with high risk non-muscle invasive BC. Whilst I recognise the vital role of chemo and 
radiotherapy play in treating this disease, and that radiotherapy may be a better choice for 
some patients than RC, it is the morbidity from RC that hinders its wider use and encourages 
alternatives [3]. For example, studies within the USA reveal that up to 1/3 of patients with 
muscle invasive cancers do not receive radical treatment [4] and implementation of 
centralised cancer services in the UK has only now shown survival improvements, as 
morbidity from RC comes down [5]. The lowering of perioperative morbidity and mortality 
from RC is changing the face of the operation and increasing its use.  
/Ŷ ƚŚŝƐ ŵŽŶƚŚ ?Ɛ ŝƐƐƵĞ ŽĨ ƚŚĞ :hŝ ? DŝůůĞƌ ĂŶĚ ĐŽůůĞĂŐƵĞƐ ĨƌŽŵ ǆĞƚĞƌ, UK combine robot-
assisted minimal access surgery with enhanced recovery to report outcomes in a consecutive 
series of  ?state of the art ? RCs [6]. The authors show consistent improvements in outcome, 
such that length of stay halves of the duration of recruitment. Importantly, recovery becomes 
more predictable (as shown by the converging mean and median length of stay figures), 
although we are unclear as to how many patients had prolonged stays. Whilst the authors 
should be congratulated for their efforts in delivering this service and for charting its 
implementation so meticulously, some key descriptive findings are missing. For example, 
what is the extent of the variation in their outcomes (range and quartiles) and do the data 
differ between surgeon? What happened to the 25% of patients who stayed longer than 10 
days? Did all patients receive all components of their ERP program, and if not, which were felt 
to be most impactful? How did length of stay and complication rates differ by reconstructive 
choice and reconstructive location (intra or extra-corporeal)? Did patient selection stay the 
same over time, or did improved ŽƵƚĐŽŵĞƐůŽǁĞƌƚŚĞ ?ĨŝƚĨŽƌĐǇƐƚĞĐƚŽŵǇ ?ďĂƌ ?Many of these 
answers will be missing, given that the primary source of information was the BAUS major 
operations registry. This self-completed dataset is extremely valuable for comparisons 
between units and trends over times, but has limited data complexity and granularity. Finally, 
whilst the field is moving towards total intra-corporeal surgery, the reported complication 
rates appear similar for extra- and intra-corporeal reconstruction, questioning need for the 
added complexity of intra-corporeal surgery. 
Economists, commissioners and patients will want to know the importance of the forces 
driving these improved outcomes. Do the better outcomes reflect centralisation of services, 
ƚŚĞ ƚĞĂŵ ?Ɛ learning curve, the meticulous use of enhanced recovery or minimal invasive 
surgery through robotics? The latter has vastly different cost implications to the others. My 
guess is that whilst all of these aspects were important, it was volume of service (from 
centralisation) and enhanced recovery that were the main contributors. I speak having seen 
a similar experience in my unit, although we started robotic surgery at a later date than these 
authors, and in the knowledge that this group previously published the dramatic impact of 
enhanced recovery on their open radical cystectomy length of stays [7]. Regardless of these 
concerns, the outcomes are to be welcomed by urologists and patients, and the team should 
be congratulated. As length of hospital stay become shorter, our next scientific focus should 
be on out of hospital recovery. We rarely see data on time taken to return to normal activity 
and on how patients adjust post-surgery. Whilst return to work is important for younger 
patients, many with bladder cancer are retired but so it is return to quality of life that matters 
most. This question becomes even more important in an era of centralised care, where many 
patients recover away from their surgical teams and conversely surgical teams are less aware 
of problems and outcomes. Perhaps it will be out of the hospital, that the effort and cost of 
minimal invasive surgery are justified. 
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